EEG-based measures (MMN, P300, 40-Hz ASSR, resting PSD) show good to excellent test-retest reliability in clinical high-risk for psychosis and control participants, supporting their use in CHR studies.
In an interim analysis of 654 CHR and 87 control participants, EEG measures demonstrated good to excellent test-retest reliability (mean G-coefficient 0.72 for CHR, 0.71 for controls). Small but significant decreases in measure magnitudes over sessions were observed, consistent with habituation, but reliability remained sufficient for use as predictors or outcome measures.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
EEG-based measures (MMN, P300, 40-Hz ASSR, resting PSD) show good to excellent test-retest reliability in clinical high-risk for psychosis and control participants, supporting their use in CHR studies. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).
The Claim
EEG-based measures (MMN, P300, 40-Hz ASSR, resting PSD) show good to excellent test-retest reliability in clinical high-risk for psychosis and control participants, supporting their use in CHR studies.
This conclusion is most relevant to: Individuals at clinical high risk for psychosis (CHR; n=654) and community controls (CON; n=87)..
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures. (Schizophrenia (Heidelberg, Germany), 2025) —
How It Works
The proposed biological pathway:
- ▸EEG measures are recorded at baseline and month-2 follow-up sessions.
- ▸Generalizability coefficients are calculated to assess test-retest reliability.
- ▸Paired t-tests evaluate changes in measure magnitudes over sessions.
- ▸Results show good to excellent reliability with small habituation effects.
Who Might Benefit
Evidence fit by population:
- ▸Individuals at clinical high risk for psychosis (CHR; n=654) and community controls (CON; n=87).
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Interim analysis with limited sample size for controls (n=87) compared to CHR group (n=654).
- ▸Small systematic habituation effects observed, which may need to be accounted for in longitudinal studies.
Frequently Asked Questions
What EEG measures were tested in this study?▼
The study tested mismatch negativity (MMN), auditory and visual P300 (P3b and P3a), 40-Hz auditory steady state response (ASSR), and resting EEG power spectral density (PSD) for traditional frequency bands.
How reliable were the EEG measures in clinical high-risk individuals?▼
The test-retest reliability was generally good to excellent, with a mean Generalizability coefficient of 0.72 (range 0.49-0.85) in the CHR group.
Did the EEG measures change over time?▼
Yes, small but significant decreases in measure magnitudes were observed over sessions (e.g., MMN, P300, 40-Hz ASSR), consistent with habituation effects.
Can these EEG measures be used in clinical trials for psychosis risk?▼
Yes, the authors conclude that the reliability is sufficiently strong to support their use as potential predictors of clinical outcomes, markers of illness progression, or secondary outcome measures in controlled clinical trials.
References
- 1.Mathalon DH, Nicholas S, Roach BJ, Billah T, Lavoie S, Whitford T, Hamilton HK, Addamo L, Anohkin A, Bekinschtein T, Belger A, Buccilli K, Cahill J, Carrión RE, Damiani S, Dzafic I, Ebdrup BH, Izyurov I, Jarcho J, Jenni R, Jo A, Kerins S, Lee C, Martin EA, Mayol-Troncoso R, Niznikiewicz MA, Parvaz M, Pogarell O, Prieto-Montalvo J, Rabin R, Roalf DR, Rogers J, Salisbury DF, Shaik R, Shankman S, Stevens MC, Suen YN, Swann NC, Tang X, Thompson JL, Tso I, Wenzel J, Zhou JH, Addington J, Alameda L, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Calkins ME, Castillo-Passi RI, Chen EYH, Choi J, Conus P, Corcoran CM, Cornblatt BA, Diaz-Caneja CM, Ellman LM, Fusar-Poli P, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Mamah D, Mittal VA, Nordentoft M, Pearlson GD, Perez J, Perkins DO, Powers AR, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Stone WS, Strauss GP, Upthegrove R, Verma SK, Wang J, Wolf DH, Zhang T, Bouix S, Pasternak O, Cho KK, Coleman MJ, Dwyer D, Nunez A, Tamayo Z, Wood SJ, Kahn RS, Kane JM, McGorry PD, Bearden CE, Nelson B, Woods SW, Shenton ME, Light GA. “The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures..” Schizophrenia (Heidelberg, Germany), 2025. PMID: 40480970 DOI: 10.1038/s41537-025-00622-0